Apr 11
|
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
|
Apr 11
|
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
|
Apr 11
|
Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug
|
Apr 10
|
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
|
Apr 10
|
argenx SE (ARGX): Among the Aggressive Stocks Picked by Hedge Funds
|
Apr 8
|
Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients
|
Apr 8
|
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
|
Mar 4
|
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
|
Feb 28
|
Argenx's Q4 Sales Backed by Vyvgart's Growth, Oppenheimer Says
|
Feb 28
|
Exploring 3 High Growth Tech Stocks in Europe
|
Feb 27
|
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
|
Feb 21
|
These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50
|
Feb 20
|
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
|
Feb 19
|
Here’s Why argenx SE (ARGX) Rose in Q4
|
Feb 19
|
Q4 2024 Halozyme Therapeutics Inc Earnings Call
|
Jan 1
|
Exploring High Growth Tech Stocks for January 2025
|
Oct 16
|
Multiple Tailwinds Lifted argenx SE (ARGX) in Q3
|
Oct 15
|
Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses'
|
Oct 15
|
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
|
Oct 9
|
argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ...
|